Stock SCYX SCYNEXIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages SCYNEXIS, Inc.

Equities

SCYX

US8112922005

Real-time Estimate Cboe BZX
Other stock markets
 17:20:50 13/05/2024 BST 		5-day change 1st Jan Change
2.085 USD +7.47% Intraday chart for SCYNEXIS, Inc. +22.23% -5.18%
05-08 Earnings Flash (SCYX) SCYNEXIS Reports Q1 Revenue $1.4M MT
05-08 SCYNEXIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
SCYNEXIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases
SCYNEXIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
SCYNEXIS, Inc. Presents Preclinical Data on Second Generation Fungerp SCY-247 Against Mucormycosis At the 11Th Advances Against Aspergillosis and Mucormycosis Conference
SCYNEXIS Amends License Agreement With GlaxoSmithKline Intellectual Property; Shares Drop Premarket
SCYNEXIS, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
SCYNEXIS, Inc. Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology
SCYNEXIS Recalls Two Lots of Brexafemme Due to Potential for Cross Contamination with Non-Antibacterial Drug Substance
SCYNEXIS, Inc. Issues A Voluntary Nationwide Recall of BREXAFEMME® (Ibrexafungerp Tablets) Due to Potential for Cross Contamination with A Non-Antibacterial ß-Lactam Drug Substance
Sector Update: Health Care Stocks Advancing Late Afternoon
Top MIdday Decliners
SCYNEXIS Recalls Brexafemme on Cross Contamination Risk; Shares Fall
SCYNEXIS, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
SCYNEXIS Says New Drug Application for Vulvovaginal Candidiasis Treatment Accepted for Review in China
Scynexis Says $25 Million Performance-Based Development Milestone Achieved as Part of GSK License Deal
Scynexis Closes Exclusive Brexafemme License Deal With GSK
SCYNEXIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
SCYNEXIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Top Midday Gainers
GSK : conclut un accord de licence exclusif avec Scynexis
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SCYX Stock
  4. News SCYNEXIS, Inc.
  5. Other languages